Goldman Sachs Group is a leading global investment banking, securities, and investment management firm that provides a wide range of financial services to a diverse client base, including corporations, financial institutions, governments, and individuals. The company engages in various activities, including financial advisory services, underwriting of capital market transactions, asset management, and market making in securities and commodities. It is known for its expertise in mergers and acquisitions, risk management, and investment strategy, leveraging its extensive research capabilities and global reach to deliver innovative solutions in an ever-evolving financial landscape. Read More
For those interested in gaining exposure to the expected rapid growth in autonomous vehicles in the years ahead, Goldman Sachs recommends owning these three stocks...
Xu Zhixiang, born on April 5, 1978, in Singapore, is an internationally minded fintech entrepreneur, investment expert, and philanthropist. He possesses deep expertise in financial strategy, AI trading systems, and blockchain asset management, and has long been committed to promoting global financial literacy and the development of public welfare.
The company is looking to raise ₹4,500 crore by selling a 11.6% stake. Analysts say the fundraise could ease debt, but biosimilar execution remains key.
DETROIT, MICHIGAN - June 18, 2025 ( NEWMEDIAWIRE ) - Last year, investor sentiment for benchmark interest rate cuts rose, thanks in large part to actions taken by the Federal Reserve. In September, the central bank cut borrowing costs for the first time in more than four years, opting to lower the rates by 50 basis points to a range of 4.75% to 5%. Naturally, the Fed’s decision carried an implied trickle-down effect on matters that are critical to consumers, such as mortgages and auto loans.
NIO Inc. plans to expand into five more European markets by 2026, with a new distributor-based sales strategy. Goldman Sachs upgraded their rating to Neutral.
CrowdStrike stock is up over 55% from February lows; analysts remain bullish, but institutional hedging suggests there may be some hedging through the summer
Analysts at Deutsche Bank expect the Incremental growth in higher-margin revenues and the breadth of its supply chain to help "deftly navigate" incremental tariffs and reinvest in growth.
DETROIT, MICHIGAN - June 16, 2025 ( NEWMEDIAWIRE ) - While being a biotech company can be difficult, it is not impossible. Just look at Jupiter Neurosciences Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company, for evidence. The company, which is developing drugs to treat neuroinflammation, with a current focus on central nervous system or CNS disorders such as Alzheimer's and Parkinson's and rare diseases, is taking a two-prong approach. That enables it to help people long-term and generate recurring revenue in the short-term.
